Indication:
Hyperlipidemias resistent to diet
Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Bezafibrate Lipid Lowering Agent January 1988
Adverse Reaction:
G.I.upset, mylagia, allergic skin reactions.
Alopecia (rare), lowers affinity to haemoglobin for oxygen.
Contra-Indications:
Advanced liver disease, primary biliary cirrhosis.
Severe renal insufficiency.
Nephrotic syndrome/hypoalbumenemia.
Pregnancy and lactation.
Special precautions:
Monitor response regularly & terminate therapy if adequate response is not achieved within 3-4 mths.
Caution in children.
Concomitant oestrogen therapy. If cholestymine being combined two drugs must be seperated by atleast 2 hours.
Dosages/ Overdosage Etc:
Indication-
Hyperlipidaemias resistent to diet
Dosage-
200mg 3 times daily after food
Children not recommended
Interaction with Food:
None reported
Pregnancy and lactation:
Use contraindicated. Observe caution
Manufacturer Details